Investors & Media

Stock Info
OTCQBBCLI
Company Information

BrainStorm (OTCQB:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Alzheimer’s Disease (AD).

Investor Presentation – October 2024

Recent News
Jun 2, 2026
BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine

Former FDA Associate Commissioner Peter Pitts and BrainStorm's Chaim Lebovits argue that regulation must keep pace with advances in biomarkers, AI, cell therapy and precision medicine NEW YORK,...

May 28, 2026
BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors

Former Senior FDA Official Joins Board as Company Prepares to Initiate Historic Phase 3b ALS Trial Under Special Protocol Assessment NEW YORK, May 28, 2026 /PRNewswire/ -- BrainStorm Cell...

May 19, 2026
BrainStorm Cell Therapeutics Announces Aggregate of $400,000 in Private Placements Priced at Premium to Market

May 19, 2026 – BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that in May it entered into...

View All

Events
Brainstorm Cell Therapeutics - Corporate Update
Monday, May 19, 2025
8:30am - 9:30am EDT

Participant Numbers:
Toll Free: 888-506-0062
International: 973-528-0011

Participant Access Code: 621608

Replay Numbers:
Toll Free: 877-481-4010
International: 919-882-2331

Replay Passcode: 52457

View All

Email Alerts
Email Alerts
Investor Contact
Investor Contact
Investor FAQs
Investor FAQs
RSS Feeds
RSS Feeds
Investors